# Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

> **NCT00679172** · PHASE2 · COMPLETED · sponsor: **Emergent BioSolutions** · enrollment: 187 (actual)

## Conditions studied

- Typhoid

## Interventions

- **BIOLOGICAL:** Dose of 5.0 x 10^9 CFU (Cohort 1)
- **BIOLOGICAL:** Dose of 7.5 x 10^9 CFU (Cohort 2)
- **BIOLOGICAL:** Dose of 1.1 x 10^10 CFU (Cohort 3)
- **BIOLOGICAL:** Dose of of 1.7 x 10^10 CFU (Cohort 4)
- **OTHER:** Placebo (Cohorts 1-4 pooled)

## Key facts

- **NCT ID:** NCT00679172
- **Lead sponsor:** Emergent BioSolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2024-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00679172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00679172, "Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00679172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*